Safety Profile of Neoadjuvant T-DXd in DB11: Balancing ILD Risk Against Anthracycline Cardiotoxicity

ILD Risk vs. Cardiotoxicity Avoided — How do the safety signals compare in DESTINY-Breast11? Drs. Pegram and Iyengar review ILD findings and the incidence of cardiac events, assessing the safety balance as it relates to administering an anthracycline-free curative regimen.